Volume 12 Supplement 1

Abstracts from the 2012 PLA Emergency Medicine Annual Congress

Open Access

Studying the therapeutic effects of hemoperfusion with continuous venovenous hemofiltration in paraquat-poisoned patients by the ratio of residual normal lung in 3D-CT image

Contributed equally
BMC Emergency Medicine201212(Suppl 1):A1

DOI: 10.1186/1471-227X-12-S1-A1

Published: 18 December 2012

Objective

Paraquat poisoning(PQ) by ingestion is often fatal and is a significant public health problem worldwide.The lung is the major target organ for PQ poisoning. The study is aimed to investigate the ratio of residual normal lung in 3D-CT image in evaluating the therapic effects of continuous venovenous hemofiltration(CVVH).

Methods

Nighty-five patients with acute paraquat poisoning were randomly divided into hemoperfusion(HP) group (46 cases) and HP-CVVH group (49 cases). The mortality, survival duration and the ratio of residual normal lung in 3D-CT image between the two groups were compared and analyzed.

Results

There were no significant differences in mortality (28.26% versus 24.49%) between the two groups on day 28 after poisoning. The mean time between poisoning and death in HP-CVVH group was (5.2±2.1) days, which was significantly longer than that (3.8±1.7) days in HP group (P<0.05). The ratio of residual normal lung in 3D-CT image on 6th day after poisoning in HP-CVVH group was (31.80±12.71)%,which was significantly higher than that (25.60±14.06)% in HP group (P < 0.05).

Conclusion

The combined therapy of HP and CVVH could prevent advances in lung injury induced by acute paraquat poisoning and prolong survival time, but failed to reduce mortality of paraquat-poisoned patients.

Notes

Authors’ Affiliations

(1)
Department of Emergency, 302 Hospital of PLA
(2)
Department of Radiology, Affiliated hospital of Academy of Military Medical Sciences
(3)
Department of Pharmacology, Academy of Military Medical Sciences

Copyright

© Peng et al; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement